ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).
Procaps Group, an integrated LatAm healthcare and pharmaceutical conglomerate, has signed a definitive agreement to buy Grupo Somar, which includes Grupo Farmacéutico Somar and Química y Farmacia and, Gelcaps and associated entities from Advent International, a private equity investor.
Artax Biopharma is set to develop its first oral small molecule immunomodulating agent, AX-158, after it closed a $26m financing round.
Asahi Kasei Medical’s US subsidiary has signed an agreement to acquire Bionova Scientific for an undisclosed amount.
Clovis Oncology and Evergreen Theragnostics have initiated a development, manufacturing, and services agreement for actinium-225-labeled-FAP-2286 (225Ac-FAP-2286).
Luye Pharma Group’s wholly owned subsidiary Yantai Luye Drugs Trading has collaborated with Beijing Biostar Pharmaceuticals’ subsidiary Chengdu Biostar Pharmaceuticals for marketing anticancer drug, Utidelone Injection, in Chinese mainland.
Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).
US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.
Synthetic biotechnology company Amyris has agreed to acquire MenoLabs, a menopause symptoms treatment company.
Pfizer has completed the collaboration transaction with Biohaven Pharmaceuticals to obtain rights to market the latter’s rimegepant and zavegepant outside of the US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.